

Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria

Joachim Pietz,¹ Roland Kreis,² André Rupp,¹ Ertan Mayatepek,³ Dietz Rating,¹ Chris Boesch,² and Hans Joachim Bremer²

¹Department of Pediatric Neurology, University of Heidelberg, D-69120 Heidelberg, Germany²Department of Magnetic Resonance Spectroscopy and Methodology, University of Berne, CH-3010 Berne, Switzerland³Department of General Pediatrics, University of Heidelberg, D-69120 Heidelberg, Germany

Address correspondence to: Joachim Pietz, Department of Paediatric Neurology, University of Heidelberg, Im Neuenheimer Feld 150, D-69120 Heidelberg, Germany. Phone: 0049-6221-562311 or 0049-6221-474157; Fax: 0049-6221-565744; E-mail: joachim_pietz@med.uni-heidelberg.de

Received August 24, 1998; Accepted March 2, 1999.

Large neutral amino acids (LNAAs), including phenylalanine (Phe), compete for transport across the blood-brain barrier (BBB) via the L-type amino acid carrier. Accordingly, elevated plasma Phe impairs brain uptake of other LNAAs in patients with phenylketonuria (PKU). Direct effects of elevated brain Phe and depleted LNAAs are probably major causes for disturbed brain development and function in PKU. Competition for the carrier might conversely be put to use to lower Phe influx when the plasma concentrations of all other LNAAs are increased. This hypothesis was tested by measuring brain Phe in patients with PKU by quantitative ¹H magnetic resonance spectroscopy during an oral Phe challenge with and without additional supplementation with all other LNAAs. Baseline plasma Phe was ~ 1,000 μmol/l and brain Phe was ~ 250 μmol/l in both series. Without LNAA supplementation, brain Phe increased to ~ 400 μmol/l after the oral Phe load. Electroencephalogram (EEG) spectral analysis revealed acutely disturbed brain activity. With concurrent LNAA supplementation, Phe influx was completely blocked and there was no slowing of EEG activity. These results are relevant for further characterization of the LNAA carrier and of the pathophysiology underlying brain dysfunction in PKU and for treatment of patients with PKU, as brain function might be improved by continued LNAA supplementation.

J. Clin. Invest 103:1169-1178 (1999)

Introduction

In phenylketonuria (PKU), an inherited disorder of amino acid (AA) metabolism (McKusick 261600), blood levels of phenylalanine (Phe) are extremely elevated because of a deficiency of phenylalanine hydroxylase (PAH; Enzyme Commission 1.14.16.1). Untreated PKU leads to disturbed brain development with profound retardation, microcephaly, epilepsy, and other neurologic symptoms, which can be widely prevented by early institution of a Phe-restricted diet. Elevated Phe levels also acutely impair brain function in early treated, and thus normally developed, patients, which was proved using neuropsychologic tasks and electroencephalogram (EEG) spectral analysis (1-3).

Because some patients are not able to adhere rigorously to the Phe-restricted diet during early years of life, and given that most patients relax or stop the diet during adolescence, alternative treatment regimens have been developed. To overcome suspected cerebral dopamine and serotonin depletion, patients with PKU who were off diet were treated with the neurotransmitter precursors tyrosine (Tyr) and tryptophan (Trp) (4). To reduce Phe influx into the brain, Berry et al. (5) supplemented the branched-chain AAs valine, isoleucine, and leucine (VIL). However, widespread acceptance could not be obtained for either of these approaches.

Despite tremendous progress in the understanding of the molecular basis of PKU, the causes of brain damage in untreated patients and of the mechanisms underlying impaired brain function occurring with acutely elevated Phe levels are still unclear. Direct effects of Phe, as well as imbalances of the large neutral amino acids (LNAAs) in brain, are thought to be major causes (6, 7).

In earlier studies, it was demonstrated that cerebral Phe can be readily detected non-invasively by proton magnetic resonance spectroscopy (¹H-MRS) (8, 9) and that quantitative ¹H-MRS can be applied to reliably determine its concentrations (9, 10). It was also shown that the influx of Phe through the blood-brain barrier (BBB) during an oral Phe challenge can be monitored by ¹H-MRS (11). The aim of the present study was to use this approach to further investigate Phe transport through the BBB in patients with PKU by manipulating blood concentrations of Phe and the LNAAs valine, methionine, isoleucine, leucine, Tyr, histidine, and Trp, while monitoring brain activity by EEG spectral analysis.

Methods

Human subjects. Six male patients with PKU were included in this study, which was approved by the Ethics Committee of the University of Heidelberg. Before the study, the experimental protocol was explained to all subjects, and their written informed consent was obtained.

The mean age of the patients was 27.6 years (range 26–30) (Table 1). None of the patients had any history of other factors disturbing brain development. Start of dietary treatment, defined by the first plasma level of Phe <600 $\mu\text{mol/l}$ after diet onset, was at a mean age of 38 days (range 24–63) after birth. Clinical phenotype was determined on the basis of Phe tolerance at five years of age (12), and standardized oral protein loading was performed mostly at the age of six years (13). Four patients (nos. 1, 2, 3, 6) still practiced a Phe-restricted diet. Long-term adult biochemical control was determined as the mean of six-month medians that were obtained from all Phe values in the last three years prior to the study.

Clinical data. Clinical evaluation (Table 1) included the identification of PAH mutations, which was based on a combination of denaturing gradient gel electrophoresis (DGGE), restriction enzyme analysis, and sequence analysis. Referring to in vitro expressions of mutations and genotype-phenotype relations, mutations were classified as either severe, moderate, or mild (12). All patients were examined with a standardized neurologic investigation, routine EEG (10/20), standard magnetic resonance imaging (MRI) examination (grading of white matter abnormalities according to Pietz *et al.* [14]), and intelligence testing (revised Wechsler Adult Intelligence Scale).

Ten healthy volunteers with a mean age of 25.3 years (range 20–46) were examined with ^1H -MRS at a single point in time to determine averaged normal ^1H -MR spectra. Their neurologic status and brain MRI scans were normal. Heterozygous status for known PAH mutations was excluded, and plasma Phe and LNAA concentrations (Table 2) were determined according to the procedures used in the patients.

Experimental protocol of Phe and LNAA intake. The study was constructed in a cross-over repeated measurement design to determine treatment effects in the six patients with PKU. Design and timing of all investigations are depicted in Figure 1. All patients were administered a single oral dose of purified L-Phe (100 mg/kg body weight; time 0 h) in each of two test series. In one series, termed Phe_{+LNAA} (solid lines in all figures), Phe intake was supplemented for 12 h with an LNAA mixture containing 150 mg/kg body weight of each of the following AAs: valine, methionine, isoleucine, leucine, Tyr, histidine, and Trp. The LNAA mixture was divided into five equal portions and started two hours before the Phe load. The subsequent four portions were taken every three hours (one, four, seven, and 10 h post load). During the experiments, the usual diet was unchanged, except that the patients still on diet did not consume their regular AA mixture. To avoid hypoglycaemia due to the intake of large amounts of free AAs, regular small meals rich in free carbohydrates and poor in protein were given during both series, always about two hours before blood drawings. The results of this Phe_{+LNAA} series were compared with an otherwise identical baseline series without LNAA intake (termed Phe_{only}; dotted lines in all figures). To control for effects of order, in three patients, the Phe_{+LNAA} series was performed first; in the others, the order was reversed. The interval between the two series was four to eight weeks. Ten days after the start of each series, plasma Phe and LNAA concentrations were monitored to ensure return to pre-treatment levels.

Amino acid analysis. Plasma Phe levels during the study were determined by an enzymatic assay (Quantase Phe assay; Porton, Cambridge, United Kingdom). Valine, methionine, leucine, isoleucine, Tyr, and histidine were analyzed by automated ion-exchange chromatography with ninhydrin, using an AA analyzer (Sykam, Munich, Germany) following standard procedures. Plasma Trp was determined by HPLC (Beckman System Gold, Palo Alto, California, USA). To compare AA plasma levels during the LNAA supplementation and the baseline period, the area under the curve was calculated for a time range from 0.5 to 11 h after Phe load. During the Phe_{only} series, plasma LNAA analysis was restricted to –0.5, 0.5, one, five, 11, and 24 h after Phe load. Blood samples for AA analysis in control subjects and for pre-treatment values in the patients were taken in the morning two hours after a light standardized breakfast.

Effects of Phe loading and LNAA supplementation on carrier-mediated Phe transport at the BBB were estimated, based on the K_m -normalized Phe ratio (ratio of Phe to the other LNAAs) regulating the influx through the BBB under AA competition for the same carrier (15):

$$K_m\text{-normalized PHE ratio} = \frac{[\text{PHE}]}{\sum \frac{K_m^{\text{Phe}} [\text{LNAA}]}{K_m^{\text{LNAA}}}}$$

In equation 1, K_m^{phe} and K_m^{LNAA} are the absolute K_m values of Phe and all other competing LNAAs, respectively, and [PHE] and [LNAA] are their respective plasma concentrations. K_m values (Table 2) determined in vivo in the conscious rat were used (16). Similarly K_m -normalized Tyr and Trp ratios were derived.

Proton MRS. To determine brain tissue concentrations of Phe, localized ^1H -MRS was performed on a routine 1.5 T MR scanner (General Electric Medical Systems, Milwaukee, Wisconsin, USA) preload (minus one hour) and six, 12, and 24 h post load. Spectra from a large volume placed above the ventricular system involving white and grey matter of both hemispheres were recorded using a quadrature head coil. Voxel volume was typically 60 × 50 × 20 mm. Axial T_2 weighted MR images were used for accurate (re-)positioning of the MRS voxel. Four spectra of 128 acquisitions were acquired in each session, using a PRESS sequence (Bottomley, Pennsylvania, USA) with outer volume suppression, water presaturation, and phase rotation (echo time 20 ms, repetition period three seconds, 2,048 data points) as described earlier (9). For the determination of different brain compartments and water referencing, a series of separate recordings with different echo times, but without water suppression, was acquired.

The data processing scheme used was similar to the one described in ref. 9. It is based on a three-compartment model (brain tissue, cerebrospinal fluid [CSF], blood) in which the visibility of plasma Phe was set to zero and the Phe content of CSF was assumed to be equal to that of brain tissue (rather than a steady-state relation with regard to plasma Phe, as assumed in ref. 9). Conversion to absolute concentration units was performed based on a proton signal density taken from the literature and on the unsuppressed water signal. The determination of the Phe peak area had been redesigned compared with ref. 9. It is

Table 1

Genetic and clinical data of patients with PKU Patient

Patient No.	Clinical PKU phenotype ^A	Mutations 1/2	Severity of mutations	PRA ^B (%)	Age (years)	Diet onset (days)	Long-term Phe last three years ^C (μmol/l)	IQ WAIS-R	Clinical neurologic symptoms	EEG evaluation	MRI grade ^D
1	Moderate	R261Q R261Q	Moderate Moderate	30% 30%	28.2	46	899	106	Tremor	Normal	4
2	Moderate	IVS10nt-11G>A P225R	Severe ?	Null ?	30.2	33	830	101	—	Normal	4
3	Moderate	R261Q G272X	Moderate Severe	30% Null	26.3	63	884	110	Tremor	Normal	8
4	Moderate	IVS12nt-1G>A R261Q	Severe Moderate	Null 30%	26.1	35	1,357	61	—	Mild	6
5	Severe	R408W	Severe	Null	26.3	28	1,304	95	—	Normal	7
6	Moderate	Not identified Y166X R261Q	(Severe?) (Severe?) Moderate	(Null?) ? 30%	28.4	24	960	112	—	Normal	1
Mean ± SD					27.6 ± 1.6	38.1 ± 14.3	1,039 ± 230	97.5 ± 18.9			

^APhe tolerance during the fifth year of life (15) and standardized oral protein loading studies at the age of six years were used for the determination of the clinical PKU phenotype. ^BPRA, predicted residual activity of phenylalanine hydroxylase. ^CLong-term Phe was determined as the mean of six-month medians obtained from all Phe values in the last three years prior to the study. ^DWAIS-R, revised Wechsler Adult Intelligence Scale. ^EMRI grading was performed as described in ref. 17.

now performed using a versatile time-frequency domain-fitting program (17) with the following steps. To parameterize normal background signals, the averaged spectrum of four normal subjects was fitted using 23 Voigt lines and a common no analytic line shape defined on the unsuppressed water peak (10 lines in the relevant downfield region). The spectrum of an aqueous 25 mm Phe model solution (pH 7.05) was similarly fitted and parameterized (11 Voigt lines to define the complicated strong coupling pattern). The combination of the two parameter sets (i.e., the models of Phe and the in vivo background signals each treated as nuclear magnetic resonance entities) was then used to determine the Phe peak areas in all in vivo spectra. Because the signal phase and line shapes were determined on the unsuppressed water signal, the peak area determination of the low signal-to-noise ratio peak of Phe was thus essentially reduced to amplitude fitting of background and Phe models in the real part of an absorption mode spectrum. This approach is illustrated in Figure 2 for a single spectrum (4 × 128 acquisitions) of a patient with PKU acquired before the Phe load (Figure 2a). The parameterized and line shape-adapted models of in vivo background signals and Phe are displayed in Figure 2, e and f, respectively, whereas the trace in Figure 2g contains the residual spectrum, i.e., original (Figure 2a) minus best fit (Figure 2d). Spectra from model solutions of the LNAA mixture as well as Tyr and Trp were recorded to rule out confounding signal contributions of the LNAAs.

Brain tissue concentrations are given in units of micromole per kilogram of wet weight. Plasma concentrations are listed in units of micromole per litre. Concentration gradients of Phe between plasma and brain are reported as dimensionless values, obtained by a unit conversion using brain and plasma density values of 1.05 kg/l.

EEG analysis. To monitor brain activity during the two series in the six patients with PKU, EEGs in the relaxed awake state with eyes closed were derived −2.5 h preload (before first LNAA intake) and −0.5 h preload (after first LNAA intake), as well as 5.5, 11.5, and 23.5 h post load immediately before the ¹H-MRS session. To control for diurnal variations of EEG spectra, Phe_{+LNAA} and Phe_{only}

were parallel with respect to the time of Phe loading and subsequent EEG investigations, thereby ensuring that diurnal variations of EEG activity were taken into account. Electrode locations were according to the 10/20 system (monopolar, common reference, F = 128 Hz, time constant = 1.0). EEG activity was digitized with 256 Hz and stored on a personal computer. From each single recording of about 10 min duration, 16–20 artifact-free sections of 4.096 s were chosen visually. Spectral analysis was performed by fast Fourier transformation. Relative power (calculated as percentage of total power within the 1.5–25 Hz range) was computed for the δ (1.5–3.5 Hz), θ (3.5–7.5 Hz), α1 (7.5–9.5 Hz), α2 (9.5–12.5 Hz), β1 (12.5–18.5 Hz), and β2 (18.5–25 Hz) bands from averaged spectra. In addition, the mean frequency of the power spectrum from 1.5 to 25 Hz (mean power frequency [MPF]), the frequency of maximum power within the α band (peak frequency [PF]), and the proportion of the power in the α band to the power in the θ band (α/θ ratio), were derived from power spectra. Statistical evaluation was restricted to lead O_z. Comparable results were determined at other locations. All EEGs were also assessed by standard visual criteria.

Statistical analysis. Statistics were computed by SAS, version 6.12 (SAS Inc., Cary, North Carolina, USA). Comparisons of means within, as well as between, the two series (Phe_{+LNAA}, Phe_{only}) were compared by Student's paired *t* tests. Because of the small number of observations, co relational analysis was done by calculation of rank co relational coefficients (Kendall's τ_b).

Results

Clinical data. On the basis of clinical data (Table 1), five patients corresponded to moderate PKU, and one patient had a severe type. Mutations were mostly typical for European patients with PKU, e.g., R408W, R261Q, G272X. In P225R, first described in a Sweden, and in Y166X, which was not described earlier, the severity of the mutations is unknown. In patient no. 5, one mutation could not be determined, despite repeated DGGE analysis. Assuming a large deletion or mutation in one of the large introns, a null mutation (residual activity <1%) is most probable. Regarding Phe tolerance at five years (12) and

data from standardized protein loading tests (13), clinical phenotype and genotype corresponded. Neurologic status was normal except for mild tremor, which was present in two patients. Long-term baseline Phe values during adult age were lower in patients on diet compared with patients off diet.

Baseline measurements. Plasma Phe was normal in all control subjects (mean $66 \pm 9 \mu\text{mol/l}$). In the six patients with PKU, preload plasma Phe values (Table 2) ranged between 796 and 1,459 $\mu\text{mol/l}$ and were thus in the typical long-term range of these patients. Mean preload plasma Phe concentrations before start of the Phe load and LNAA treatment did not differ between both series ($t = 0.76$, not significant [ns]). Mean pre-treatment plasma concentrations of all other LNAAs (Phe_{+LNAA} -10 and -2.5 h; Phe_{only} -0.5 h) were also comparable for the two series (Table 2 and Figure 3). Before the Phe load, mean K_m -normalized Phe ratios of 5.7 and 5.6 resulted for the Phe_{only} and the Phe_{+LNAA} series, respectively (Table 3), in comparison with a mean K_m -normalized Phe ratio of 0.33 ± 0.04 in the control subjects. Preload K_m -normalized Tyr and Trp ratios for the PKU patients were 0.015 and 0.026, respectively, in

both series (Table 3), compared with 0.09 (Tyr ratio) and 0.19 (Trp ratio) in the control subjects.

In all 12 preload ¹H-MR spectra of the patients, excess Phe peaks at 7.37 pm were identified; these peaks are attributed to the phenyl protons of Phe. Figure 2 contains the spectrum for one patient before the Phe load in the Phe_{only} series (plasma Phe of 1,193 μM ; brain Phe 265 $\mu\text{mol/kg}$) and demonstrates the signal-to-noise ratio achieved for single data points. Absolute brain tissue concentrations of Phe are listed in Table 3. Mean statistical uncertainty of a single brain Phe measurement (mean SEM of four spectra for each session) was 17 and 19 $\mu\text{mol/kg}$ for the Phe_{only} and Phe_{+LNAA} series, respectively, i.e. ~7% of the measured values. Preload brain Phe concentrations were not significantly different ($t = 1.4$, ns) for the two series. However, the mean plasma/brain ratio was somewhat lower during the Phe_{only} series ($t = 2.05$, $P < 0.10$). Preload plasma and brain Phe concentrations correlated significantly during the Phe_{only} series ($\tau_b = 0.87$, $P < 0.05$) but not during the Phe_{+LNAA} series ($\tau_b = 0.33$, ns).




Figure 1.

Study design. In the Phe_{only} series (left), plasma concentrations of Phe and the other LNAAs were determined during an oral Phe load. Brain tissue concentrations of Phe were measured with in vivo ¹H-MRS. Brain activity was monitored using spectral analysis of EEG activity. In the Phe_{+LNAA} series (right), this experiment was supplemented by LNAA treatment with $5 \times 30 \text{ mg/kg}$ body weight.

Dynamic data during Phe and LNAA intake. After the oral Phe load, plasma Phe values (Figure 3a) steeply increased to reach a maximum one hour post-load during both series and slowly decreased thereafter. In the Phe_{only} series, plasma Phe increase in comparison with preload values was 82% ($854 \pm 101 \mu\text{mol/l}$) six hours post-load, 78% ($802 \pm 133 \mu\text{mol/l}$) 12 h post-load, and 63% ($657 \pm 123 \mu\text{mol/l}$) 24 h post-load. In the Phe_{+LNAA} series, plasma Phe increase was 75% ($797 \pm 368 \mu\text{mol/l}$) six hours post-load, 55% ($579 \pm 238 \mu\text{mol/l}$) 12 h post-load, and 38% ($405 \pm 212 \mu\text{mol/l}$) 24 h post load. Comparing plasma Phe concentrations in the two series, these were similar six hours post load ($t = 0.02$, ns). In the Phe_{+LNAA} series, plasma Phe was 9% lower 12 h post load ($t = 2.5$, $P < 0.10$) and 12% lower 24 h post load ($t = 3.6$, $P < 0.05$) in

comparison with the Phe_{only} series. Phe levels had decreased by 17% (Phe_{only}) and 20% (Phe_{+LNAA}), respectively, at 24 h compared with maximum Phe at one hour post-load. Ten days later, Phe levels had returned to preload values in both series and in all patients.

During the Phe_{only} series, plasma concentrations of some other LNAAs decreased slightly in the post-load period (Table 2). This was statistically significant for isoleucine ($t = 3.8$, $P < 0.05$) and Trp ($t = 6.7$, $P < 0.01$). During the Phe_{+LNAA} series, LNAA supplementation started at minus two hours and led to a substantial increase in plasma LNAA concentrations in all seven AAs (Table 2). The courses of valine (Figure 3b), methionine, isoleucine, and leucine plasma concentrations from preload to 12 h post-load showed a marked jitter, attributed to both fast absorption

Table 2

Plasma LNAA concentrations in patients with PKU

LNAAs	K_m values (μmol) ^A	Control ^B $n = 10$ ($\mu\text{mol/l}$)	Phe _{only} series (baseline) 100 mg/kg				
			Pretreatment Phe -0.5 h LNAA -0.5	Postload six hours ^C	Postload 12 h ^C	Treatment Mean 0.5–11 h ^C	Postload 24 h ^C
Phenylalanine	32 ± 9	66 ± 9	1,036 ± 199	1,890 ± 244***	1,838 ± 181***	1,893 ± 203***	1,693 ± 196***
Valine	168 ± 72	211 ± 33	218 ± 59	204 ± 48	237 ± 21	198 ± 34	215 ± 55
Methionine	83 ± 16	41 ± 6	33 ± 8	30 ± 16	32 ± 11	27 ± 8	27 ± 5
Isoleucine	145 ± 29	67 ± 12	71 ± 14	54 ± 17*	68 ± 135	53 ± 14*	57 ± 18**
Leucine	87 ± 11	128 ± 22	136 ± 21	120 ± 42	135 ± 32	115 ± 37	109 ± 36*
Tyrosine	86 ± 17	59 ± 11	43 ± 7	40 ± 11	54 ± 13	39 ± 9	47 ± 13
Histidine	164 ± 28	82 ± 9	85 ± 14	74 ± 15	82 ± 8	73 ± 12	78 ± 10
Tryptophan	52 ± 14	68 ± 13	49 ± 10	34 ± 9**	41 ± 9*	35 ± 8**	34 ± 6**
Lysine	—	178 ± 33	161 ± 33	150 ± 48	170 ± 63	146 ± 41	155 ± 49

^A K_m values of AA transport at the blood-brain barrier determined in the conscious rat, according to ref. 19; the K_m of lysine, which does not belong to the group of LNAAs, was not determined. ^BNormal data were obtained from 10 healthy subjects who also served in the determination of normal reference ¹H-MR spectra. ^CSignificance values are given for differences

from the gastrointestinal tract and fast elimination from blood, whereas the courses of Tyr, histidine, and Trp (Figure 3c) concentrations were found to be smoother. During LNAA treatment, lysine concentrations decreased by ~30%. As lysine levels also slightly decreased in the Phe_{only} series compared with pre-treatment levels (Table 2), there was no significant difference between the series ($t = 1.9$, $P = 0.11$). However, an effect of LNAA treatment on plasma lysine levels has to be assumed. Also, other AAs showed a slight decrease of plasma concentrations post load. This effect was present in both series, e.g., ornithine Phe_{only} series: $-14 \mu\text{mol/l}$, approximately -18% ; Phe_{+LNAA} series: $-10 \mu\text{mol/l}$, approximately -12% , compared with pre-treatment levels. Most LNAA concentrations and lysine were back in the pre-treatment range 14 h after stopping LNAA supplementation, i.e., 24 h after the Phe load. However, mean concentrations for methionine (+196%), Tyr (+43%), and histidine (+20%) were still above pre-treatment levels. Ten days after the Phe load, all LNAA levels were in the pre-treatment range.

The K_m -corrected Phe/LNAA ratio (Table 3 and Figure 3d) more than doubled in the Phe_{only} series, whereas it decreased under LNAA treatment, i.e., up to 12 h. In the Phe_{only} series, K_m -normalized Tyr and Trp ratios decreased. However, in the Phe_{+LNAA} series, they increased despite elevation of plasma Phe.

In vivo ¹H-MRS (Figures 3e and 4) revealed totally different courses of cerebral Phe levels with and without LNAA supplementation. The data from the Phe_{only} series confirmed that an increase in plasma Phe leads to a significant, but delayed, increase of Phe concentrations in brain tissue (preload to six hours post-load; $t = 6.4$, $P < 0.01$). On average, this increase still continued after 12 h, and brain Phe levels were higher at 24 h compared with 12 h post-load (Table 3). Total increase from preload to 24 h post-load was 64%. During the Phe_{+LNAA} series, the influx of Phe into brain tissue was totally blocked for 12 h (Figure 3e). From preload to 12 h post-load, brain Phe even decreased by 5%, although this difference was not significant ($t = -1.2$, ns). After stopping LNAA supplementation, brain Phe also increased during the Phe_{+LNAA} series. Total increase from preload to 24 h post-load was 41% in the Phe_{+LNAA} series ($t = 3.8$, $P < 0.05$).

The effects of Phe loading during the two series are also viewed in Figure 4. The differing sizes of the Phe peaks from difference spectra (PKU minus control) reflect the differing cerebral Phe levels. Because of a delayed influx from plasma into brain tissue, plasma/brain ratios of Phe (Figure 3f) increased during the Phe_{only} series from preload (4.0) to six hours (5.3) and 12 h (4.7) post-load. This ratio returned to preload values 24 h post-load (4.2). As plasma Phe concentrations increased, and brain Phe remained stable, the increase of the plasma/brain ratio six hours and 12 h post-load was much more pronounced during the Phe_{+LNAA} series.

The ¹H-MR spectra did not show contributions from any of the supplemented LNAAs. In particular, there was no indication for a doublet at 1 pm that would be characteristic for valine, which reached almost 1 mm n plasma.

Monitoring brain activity by EEG spectral analysis. The effect of Phe intake on EEG activity (Table 3 and Figure 5) was also different for the two series. Although the individual profiles of the power spectra were reproduced in all EEG derivations of both series, a shift of the dominant peak of background activity to the lower-frequency spectrum was observed for the Phe_{only} series from six hours post-load onward. This dominant peak was located in the center of the α band in five patients. Figure 5 contains the averaged EEG power spectra of all six patients from -2.5 h preload to 24 h post-load. Calculation of the relative power in conventional frequency bands confirmed Phe-related changes in EEG spectra. A significant increase of θ activity from preload to 24 h post-load ($t = 3.6$, $P < 0.05$) was accompanied by a simultaneous decrease of $\alpha 2$ activity ($t = -3.5$, $P < 0.05$). Consequently, the α/θ ratio decreased continuously from preload to 24 h post-load in the Phe_{only} series. Similarly, PF ($t = -6.0$, $P < 0.01$) and MPF ($t = -4.9$, $P < 0.01$) decreased by 0.4 Hz (Table 3). These changes were noted in all six patients; δ , $\alpha 1$, and β activity were unchanged.

During the Phe_{+LNAA} series, comparable effects were not observed (Figure 5). EEG power spectra from -2.5 h preload (before first LNAA intake) and -0.5 h preload (after first LNAA intake) were comparable. An increase in fast α activity, as well as PF and MPF, was observed in EEGs 12 h post-load, i.e., around midnight. The following

morning, which was 24 h after Phe intake, EEG activity was not significantly different compared with preload measurements. Comparing Phe_{only} and Phe_{+LNAA} series, differences were statistically significant for θ activity 24 h post-load, α_2 activity 12 and 24 h post-load, as well as the α/θ ratio 12 and 24 h post-load (Table 3).

Visual evaluations of all EEG recordings from both series revealed no abnormalities. In particular, abnormal EEG patterns, like epileptiform activity, were not observed. During both Phe_{only} and Phe_{+LNAA} series, no side effects were registered, except for feelings of satiation after LNAA intake. Blood glucose levels were above 4.4 mmol/l at regular checks. Standard laboratory evaluations (red and white blood cell counts, electrolytes, transaminases) remained in the normal range.

In this study, brain Phe concentrations were measured by means of in vivo ¹H-MRS in two series of AA loading

experiments in patients with PKU. Our results prove that despite significantly increasing plasma Phe values, cerebral Phe concentrations remained unchanged, or were even lowered, during concomitant high-dose oral intake of an LNAA mixture. Although a complete block of Phe influx seems to be the most plausible explanation, other mechanisms (e.g., influences on cerebral Phe metabolism as well as AA efflux from brain) have to be considered. It was shown that high brain Phe concentrations cause a slowing of electrical brain activity and that this effect can be avoided by LNAA supplementation. These main results are relevant to basic research addressing the properties of the LNAA carrier through the BBB and to understanding the biochemical mechanisms underlying brain dysfunction in PKU. They are also significant for treatment of patients with PKU.




Figure 2.

Downfield portion of the ¹H-MR spectrum. (a) Spectrum of a 26-year-old patient with PKU. (b) The averaged spectrum of 10 healthy age-matched subjects, and (c) the corresponding spectrum of an aqueous solution of Phe. The right side illustrates the model-fitting procedure used. Spectrum (d) contains the best-fitting model for spectrum a, which is composed of a parameterized spectrum of normal background and residual water signals (e) as well as the parameterized spectrum of Phe (f). Trace (g) contains the residuals of the best fit (i.e., a–d) for this case.

LNAA carrier system. Normal brain development and function depend on the continuous influx of nutrients through the BBB. Therefore, the properties of specific transport systems have been an essential issue in the understanding of physiological as well as pathophysiological conditions. For LNAAs, net uptake through the BBB is determined by their ratio in plasma and their different affinity to the stereospecific L-type AA carrier system (18–21). Carrier saturation and competitive inhibition of the influx of other LNAAs can be expected at supraphysiological plasma Phe levels usually found in PKU and may be present already at concentrations in the range of 200–500 $\mu\text{mol/l}$ (18). The K_m -normalized Phe/LNAA ratio was calculated using measured plasma concentrations and K_m values from the literature. It predicted that in the Phe_{only} series, the increase of plasma Phe should lead to a further increase in brain Phe uptake, whereas in the Phe_{+LNAA} series, brain Phe uptake should decrease despite doubled plasma Phe. The ¹H-MRS and EEG measurements

presented prove these predictions to be correct and the underlying model valid.


The applicability of such a simple model to the in vivo situation is surprising because the calculation of LNAA transport on the basis of apparent K_m values under non-steady state conditions obviously disregards some important aspects. First, it may appear questionable to use K_m values obtained in an animal study, but there exists agreement in the literature that K_m values can be transferred from animals to humans (16, 18, 19, 21). Second, K_m values reported in the literature vary to some degree, even within one species, depending on the experimental approaches used. However, the main results from using the equation for competing enzyme kinetics are well reproduced, even when other sets of K_m values are used (19, 20). Only the use of K_m values determined in vitro in isolated human capillaries (21) produced somewhat different results, with smaller effects of LNAA competition. This confirms that results from in vitro studies cannot directly be transferred to the in vivo situation. Third, AA uptake by the brain cannot be

Table 3

Plasma and brain Phe concentrations, K_m -normalized Phe/LNAA ratio, plasma/brain Phe ratio, and EEG spectral parameters in PKU patients as function of time

	Phe _{only} series (baseline)				Phe _{+LNAA} series 100 mg/kg Phe at time 0 h			
	Preload	Postload six hours	Postload 12 h	Postload 24 h	Preload	Postload six hours	Postload 12 h	Postload 24 h
Plasma Phe ($\mu\text{mol/l}$) ^A	1,036 ± 199	1,890 ± 244***	1,838 ± 181***	1,693 ± 196***	1,063 ± 189	1,887 ± 235**	1,669 ± 168**	1,495 ± 128**
K_m -normalized Phe ratio ^A	5.7 ± 1.4	12.0 ± 1.7**	10.3 ± 2.2**	11.1 ± 2.4**	5.6 ± 2.0	2.4 ± 0.4**	2.1 ± 0.4**	6.4 ± 1.5
K_m -normalized Tyr ratio ^A	0.015 ± 0.003	0.007 ± 0.002*	0.01 ± 0.003	0.01 ± 0.003	0.015 ± 0.007	0.028 ± 0.007***	0.032 ± 0.007**	0.015 ± 0.004
K_m -normalized Trp ratio ^A	0.026 ± 0.006	0.011 ± 0.003***	0.013 ± 0.003***	0.012 ± 0.002***	0.026 ± 0.009	0.057 ± 0.009**	0.055 ± 0.011**	0.019 ± 0.005
Brain Phe ($\mu\text{mol/kg wet weight}$) ^A	252 ± 73	344 ± 54**	377 ± 80**	397 ± 88**	226 ± 52	235 ± 33	210 ± 31	309 ± 45*
Plasma/brain ratio Phe ^{A,B}	4.0 ± 0.4	5.3 ± 0.6**	4.7 ± 0.6**	4.2 ± 0.6	4.6 ± 0.9	7.9 ± 2.0**	7.7 ± 1.4**	4.7 ± 0.7
EEG: θ band (%) ^C	19.6 ± 11.5	24.1 ± 14.7	23.5 ± 14.8	24.8 ± 13.8	16.1 ± 5.5	15.5 ± 6.3	13.4 ± 4.1 [‡]	19.3 ± 10.7**
EEG: $\alpha 2$ band (%) ^C	16.2 ± 10.2	13.2 ± 9.4	14.2 ± 9.1	11.3 ± 9.1	16.5 ± 9.8	16.9 ± 7.7	26.8 ± 13.0*	16.7 ± 10.7**
EEG: α/θ ratio ^C	4.5 ± 4.2	3.8 ± 3.0	3.5 ± 2.7	3.0 ± 2.1	4.5 ± 1.8	4.9 ± 2.4	5.6 ± 2.5**	4.1 ± 2.4**
EEG: PF (Hz) ^C	9.7 ± 0.5	9.3 ± 0.6	9.5 ± 0.9	9.2 ± 0.5	9.7 ± 0.5	9.7 ± 0.3	10.1 ± 0.7 [‡]	9.3 ± 0.7
EEG: MPF (Hz)	9.3 ± 0.6	9.1 ± 0.9	9.3 ± 1.1	8.8 ± 0.8	9.5 ± 0.3	9.4 ± 0.3	9.8 ± 0.3	9.2 ± 0.5

^ASignificance values are given for differences between preload and postload values within the two series: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. Because of repeated use of the preload data, significance with $P < 0.05$ should be treated with caution. ^BFor the calculation of ratios, brain tissue concentrations were transformed to $\mu\text{mol/l}$ according to a brain tissue density of 1.05 g/l. ^CBecause of diurnal EEG variations, significance values are given for differences between the Phe_{only} and Phe_{+LNAA} series: [‡] $P < 0.10$ (AUTHOR: edit to P-value correct? Please check this and others carefully), * $P < 0.05$, ** $P < 0.01$.

**Figure 3.**

Time course of plasma and brain Phe and examples for LNAAs. (a) Step increase of plasma Phe levels after an oral dose of L-Phe (time 0 h) in the Phe_{only} (dotted line) and Phe_{+LNAA} series (solid line). (b) Plasma concentrations of valine and (c) tryptophan are given as examples of LNAA increase during LNAA supplementation in the Phe_{+LNAA} series (solid line), compared with the Phe_{only} series (dotted line). (d) K_m -corrected Phe/LNAA ratio versus time after load. During Phe_{only}, this ratio increased because of the increase in plasma Phe; it decreased during LNAA treatment. (e) Brain Phe concentrations as determined by in vivo ¹H-MRS demonstrating a continuous increase during Phe_{only} and a block of Phe influx during LNAA treatment. (f) The ratio of plasma/brain Phe increased much more with LNAA treatment than without. All curves represent the average values from all six patients.

fully described by a simple two-compartment model. AA transport also occurs at cellular and intracellular membranes (22). Thus, the distribution of AAs into different compartments and fluid spaces, as well as efflux from brain, ought to be considered (23, 24). Furthermore, glia and neuronal cells seem to be different with regard to their free AA pools (24). However, it appears that LNAA

uptake via the high-affinity L-type carrier at the endothelial wall constitutes the rate-limiting step under physiological conditions. Finally, the role of adaptive processes is still quite unclear. Based on results obtained with the double-indicator method, Knudsen et al. (25) speculated that inter-individual differences between patients with PKU with regard to K_m and V_{max} could be explained by an up

regulation of the number of BBB carriers. The individual time courses of our measured brain versus plasma Phe levels (not shown) appear to confirm a large individual spread in kinetic parameters.

¹H-MRS. As in earlier studies (8, 9, 11), it was possible to quantitate by ¹H-MRS cerebral Phe concentrations in patients with PKU, thereby confirming the usefulness of ¹H-MRS for the quantitative study of inborn errors of metabolism in general and PKU in particular. The presented results for the steady-state plasma/brain ratio for Phe are in close accordance with our earlier values (average of 4.0 for preload values of the Phe_{only} series versus 4.1 in ref. 11).

The preload values of Phe were somewhat different between the two series. It seems quite possible that this small difference is caused by the first dose of LNAA taken before the baseline measurement. This explanation is supported by the finding that plasma and brain values correlate significantly for the Phe_{only} but not for the Phe_{+LNAA} series. It indicates that an increase in plasma LNAA concentration without Phe challenge might be used to lower steady-state brain Phe levels.

With the current setup of ¹H-MRS data acquisition and processing, brain Phe concentrations down to 100 μmol/kg can be determined reproducibly. This corresponds to a detectable proton density of 500 μmol/kg. Given this detection threshold and the spectral pattern of valine (six protons in an up field doublet), one can estimate that brain valine content remains below 500 μmol/kg when plasma valine is between 600 and 900 μM. Similarly, we did not detect any interfering signals from Trp, Tyr, or histidine in the downfield region during the LNAA series.

With the detection limit achieved, ¹H-MRS is a suitable non-invasive method to characterize the LNAA uptake at the BBB even in healthy subjects. However, it has to be taken into account that cerebral Phe concentrations are determined not only by AA influx but also by efflux and metabolism. These factors, which contribute to cerebral AA concentrations, in principle can be de-convoluted either by dynamically fitting the time course of cerebral Phe elevations or by the use of isotopically labelled precursors. This approach is particularly promising, as alternatives (25, 26) are invasive, requiring puncture of the internal jugular vein or application of radioisotopes, and are based on various assumptions.

Möller et al. (27) tried to determine the kinetic characteristics of Phe transport at the BBB by use of steady-state ¹H-MRS measurements and, analogous to glucose transport kinetics (28), application of symmetric Michaelis-Menten kinetics with an arbitrary constant Phe consumption rate. This method strongly relies on data obtained from patients with extremely high plasma Phe values and is also susceptible to nonlinearities in Phe quantitation. Their apparent K_m and T_{max}/V_{max} values do not concur well with the current data if the same simplified model is applied.

Pathophysiology of PKU. The biochemical mechanisms leading to impaired brain development and function in PKU are still the subject of research. Direct effects of elevated Phe concentrations on several enzyme systems, and consequences of a concomitant depletion of other LNAAs in the brain, are thought to be the most important factors for the disturbed brain development in untreated PKU (7).

Research has focused on myelin synthesis and turnover, protein synthesis, and amine neurotransmitters. Significant effects were observed with regard to the initiation and further processing of protein synthesis (29). Hyperphenylalaninemia led to a loss of several AAs, especially LNAAs, in the brain of newborn mice, with a concomitant decrease in the incorporation of AAs into protein. Interestingly, the co administration of LNAAs prevented this effect (30). However, the significance of animal models using experimentally induced Hyperphenylalaninemia (29, 30) remains questionable because of uncontrolled side effects of the PAH inhibitors used, e.g., α-methyl phenylalanine.

In addition to their long-term impact on brain structure, high Phe concentrations have acute effects on brain function. However, it is possible that thresholds for acute Phe effects and chronic Phe neurotoxicity in the developing brain are different. It has been discussed that impaired synthesis of serotonin and dopamine could underlie these effects. Krause and colleagues (1, 2) found correlations between high plasma Phe levels with decreased performance on neuropsychologic tests of higher integrative function and characteristic changes in the power spectrum of the EEG. As Phe increase led to a concomitant decrease in plasma L-dopa, it was speculated that brain function might be impaired through inhibition of catecholamine synthesis. However, concentrations of neurotransmitters and their metabolites in blood show only a slight relation to the concentration in CSF and even less to that in neuronal cells.




Figure 4. Averaged ¹H-MRS difference spectra (patients minus averaged normal spectra), acquired in vivo before as well as 6, 12, and 24 h after the oral Phe load. The increase of the Phe peak at 7.37 ppm during the Phe_{only} series (dotted line) contrasts with the unchanged Phe peak 6 and 12 h post load in the Phe_{+LNAA} series (solid line). When LNAA treatment was stopped, brain Phe also increased in this series (measurement at 24 h).

In this study, serial EEG spectral analysis was used to monitor brain activity of patients with PKU during Phe loading. EEG spectral analysis is free of learning effects and is, therefore, an effective and reliable method to evaluate Phe-related impairments of brain function. Because of diurnal variations, comparison of EEG parameters was restricted to parallel measurements between the two series, as well as to preload and 24 h post load measurements within the series. Our results confirmed the occurrence of specific changes in the frequency spectrum of the EEG background activity with high brain Phe concentrations, which were seen earlier in children (1) and adults (3) with PKU.

Disturbances of the free AA pools of the brain may have further implications for brain function because, in addition to serotonin and dopamine, other AAs (e.g., glutamate, aspartate, glycine) serve as neurotransmitters (32, 33). As these AAs use different carrier systems, BBB transport and resulting intracerebral concentrations should not be disturbed during LNAA treatment if plasma levels are not substantially affected. Thus, further LNAA studies should include monitoring of the entire plasma AA profile. Monofunctional explanations, such as the “dopamine depletion hypothesis” (33), disregard the a priori multifunctional character of impairments of brain development and function in PKU. Finally, the causes for acute Phe neurotoxicity, as reflected by the slowing of EEG activity, remain unclear.

Treatment of PKU. Our results have direct implications for the treatment of PKU which was introduced more than 40 years ago (34). In contrast to earlier suggestions that dietary treatment may be terminated after the most vulnerable period of fast brain development and myelin stabilization, there has in recent years been a strong urge toward a strict “diet for life” in some metabolic centers (35). Despite recommendations to continue diet in adult life, most patients relax or stop diet in adolescence (36, 37). Thus, alternative treatment regimes were developed to compensate for the relaxed Phe restriction.

Evidence from in vitro and animal studies, as well as from AA analyses of human CSF, suggests that high Phe concentrations inhibit dopamine and serotonin synthesis. Consequently, high-dose supplementation of the precursor substances Tyr and Trp was tried as an alternative therapeutic approach for adolescent and adult patients off diet (4). However, a substantial benefit of high-dose Tyr could not be confirmed in placebo-controlled studies (38).

The VIL treatment (150 mg/kg valine, 150 mg/kg isoleucine, and 200 mg/kg leucine) was designed to inhibit Phe influx into the brain. Although plasma concentrations of Phe remained unchanged, a ~20% decrease of Phe concentrations in CSF seemed to confirm the hypothesis. In addition, improvements on a neuropsychologic task were shown for VIL treatment (5, 39). The VIL approach was also used in an animal model of maternal PKU (40). Rats exposed to high phenylalanine levels in utero showed characteristic learning deficits, which could be prevented by VIL treatment. Long-term VIL treatment did not show any side effects. However, as criticized by Hommes (41), CSF Tyr concentrations were lowered further during VIL treatment. It was also noted that the rate at which protein synthesis may be reduced in the PKU brain will depend on the supply of all essential AAs. Thus, the increase of only

one (Tyr) or three (VIL) AAs may even accentuate disturbances of neurotransmitter or protein synthesis (42). VIL therapy did not find acceptance in PKU treatment. In the present study, K_m -corrected Tyr, and Trp ratios improved during LNAA supplementation, even under the condition of steeply increasing plasma Phe levels.

To date, there exists only one report on the use of LNAAs in human PKU. In addition to a Phe-restricted diet, Dotremont et al. (43) used a supplement of 0.8 g/kg body weight LNAA mixture. This was well tolerated without adverse effects. Laboratory evaluations were all normal, except for extremely low lysine levels. Also, in our study, a reversible ~30% decrease of plasma lysine was noticed during LNAA treatment. The causes for this effect are unclear. One possible explanation for this phenomenon could be a stimulation of protein synthesis. However, this result highlights the necessity of careful AA monitoring during supplementation trials. Referring to animal studies that proved lysine deficiency in hyperphenylalaninemic rats, Huether et al. (44) noted that additional lysine supplementation should be considered in PKU treatment. Unfortunately, further data highlighting cerebral Phe concentrations or evaluations of brain function were not reported by Dotremont et al. (43). Before use in the present study, identical LNAA supplementation was studied in three other adult control subjects with normal Phe plasma levels. This trial showed no side effects, and EEG spectra were not influenced by LNAA intake (data not shown).

In standard dietary treatment of PKU, large amounts of free AAs are consumed to compensate for the Phe-restricted, and hence, also natural protein-restricted, diet. The present results now raise the question whether such a regular AA mixture may have the previously unexpected effect of lowering brain Phe in addition to replacing natural protein. Ris et al. (45) found negative correlations between verbal intelligence quotient (IQ) and age when formula use was discontinued in adult patients with PKU. This correlation was even stronger than the association of verbal IQ and age when Phe exceeded 1,200 $\mu\text{mol/l}$. Whether patients off diet might profit from the continuing intake of AA mixtures was considered. This speculation is supported by our results. In addition, the profiles of LNAA increase (Figure 3) after repeated oral intake elucidate intestinal resorption kinetics and elimination from plasma. These aspects as well as the specific K_m values of the AAs used should be considered in further experiments to obtain a more balanced pattern of LNAA concentrations.

Recently, the metabolic effects resulting from large intakes of AA mixtures have been reported (46). The recommended daily amount of ~1.6/kg body weight AA mixture was given in a single dose to control subjects, leading to a substantial increase of AAs. For example, leucine increased from ~100 $\mu\text{mol/l}$ preload to ~350 $\mu\text{mol/l}$. Thus, AA increases were nearly in the range of AA concentrations measured in our study. Side effects of AA intake included an increase of insulin in plasma, leading to significant decreases in blood glucose. Most of these side effects, however, could be prevented by dividing the single dose into three portions per day.


In conclusion, these results show that transport kinetics of carrier systems at the BBB can be quantified non-invasively by $^1\text{H-MRS}$. Evidence is provided that LNAA supplementation blocks Phe influx at the BBB and prevents

disturbances of brain electrical activity caused by high cerebral Phe concentration in an acute-phase study. Further studies in patients with PKU who are off diet are now warranted to determine whether brain Phe concentration

can be lowered during steady state and whether brain function can be improved by long-term continued LNAA supplementation.

Figure 5.

Averaged EEG power spectra from patients with PKU. During the Phe_{only} series (dotted line), a shift of the dominant peak of EEG background activity to the lower-frequency spectrum is demonstrated, which was prevented by LNAA treatment (solid line).



Acknowledgments

Supported by the German Research Foundation (Pi196/3-1), the Medical Faculty University of Heidelberg (69/1996), and the Swiss National Foundation (31-43280.95). The authors thank J. Zschocke (Department of Paediatrics, University of Marburg, Marburg, Germany) for determination of PAH mutations.

References

1. Krause W, Epstein C, Averbook A, Dembure P, Elsas L. Phenylalanine alters the mean power frequency of electroencephalograms and plasma L-DOPA in treated patients with phenylketonuria. *Pædiatr Res.* 1986; **20**:1112–1116.
2. Krause W, et al. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. *J Clin Invest.* 1985; **75**:40–48.
3. Pietz J, et al. EEGs in phenylketonuria. I. Follow-up to adulthood. II. Short-term diet-related changes in EEGs and cognitive function. *Dev Med Child Neurol.* 1993; **35**:54–64.
4. Lou HC. Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria [letter] *Lancet.* 1985; **2**:150–151.
5. Berry HK, Brunner RL, Hunt MM, White PP. Valine, isoleucine and leucine. A new treatment for phenylketonuria. *Am J Dis Child.* 1990; **144**:539–543.
6. Scriver, C.R., Kaufman, S., Eisensmith, R.C., and Woo, S.L.C. 1995. The Hyperphenylalaninemia. In *The metabolic basis of inherited disease, volume 1*. 7th edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill. New York, NY. 1015–1075.
7. Kaufman, S. 1977. Phenylketonuria: biochemical mechanisms. In *Advances in neurochemistry, volume 2*.

B.W. Agranoff and M.H. Aprison, editors. Plenum Press. New York, NY. 1–132.

8. Novotny EJ, et al. *In vivo* measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. *Paediatr Res.* 1995; **37**:244–249.
9. Kreis R, Pietz J, Penzien J, Herschkowitz N, Boesch C. Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of *in vivo* ¹H magnetic resonance spectroscopy. *J Magn Reson B.* 1995; **107**:242–251.
10. Kreis R. Quantitative localized ¹H-MR spectroscopy for clinical use. *Prog NMR Spectroscopy.* 1997; **31**:155–195.
11. Pietz J, et al. The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by *in vivo* ¹H magnetic resonance spectroscopy. *Paediatr Res.* 1995; **38**:1–7.
12. Guldberg P, et al. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. *Am J Hum Genet.* 1998; **63**:71–79.
13. Lutz P, Schmidt H, Frey G, Bickel H. Standardized loading test with protein for the differentiation of phenylketonuria from Hyperphenylalaninemia. *J Inherit Metab Dis.* 1982; **5**:29–35.
14. Pietz J, et al. Phenylketonuria: findings at MR imaging and localized *in vivo* H-1 MR spectroscopy of the brain in patients with early treatment. *Radiology.* **201**:413–420.
15. Pardridge, W.M. 1988. Phenylalanine transport at the human blood-brain barrier. In *Dietary phenylalanine and brain function*. R.J.Wurtman and E. Ritter-Walker, editors. Birkhäuser. Boston, MA. 56–62.
16. Miller L, Braun LD, Pardridge WM, Oldendorf WH. Kinetic constants for blood-brain barrier amino acid transport in conscious rats. *J Neurochem.* 1985; **45**:1427–1432.

17. Slotboom J, Boesch C, Kreis R. Versatile frequency domain fitting using time domain models and prior knowledge. *Magn Reson Med*. 1998; **39**:899–911.
18. Pardridge WM. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. *Neurochem Res*. 1998; **23**:635–644.
19. Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. *Biochim Biophys Acta*. 1975; **401**:128–136.
20. Smith QR, Momma S, Aoyagi M, Rapport SI. Kinetics of neutral amino acid transport across the blood-brain barrier. *J Neurochem*. 1987; **49**:1651–1658.
21. Hargreaves KM, Pardridge WM. Neutral amino acid transport at the human blood-brain barrier. *J Biol Chem*. 1988; **263**:19392–19397.
22. Herrero E, Aragon MC, Gimenez C, Valdivieso F. Inhibition by L-phenylalanine of tryptophan transport by synaptosomal plasma membrane vesicles: implications in the pathogenesis of phenylketonuria. *J Inherit Metab Dis*. 1983; **6**:32–35.
23. Knudsen GM, Pettigrew KD, Patlak CS, Hertz MM, Paulson OB. Asymmetrical transport of amino acids across the blood-brain barrier in humans. *J Cereb Blood Flow Metab*. 1990; **10**:698–706.
24. Lajtha, A.L., Maker, H.S., and Clarke, D.D. 1981. Metabolism and transport of carbohydrates and amino acids. In *Basic neurochemistry*. G.J. Siegel, R.W. Albers, B.W. Agranoff, and R. Katzman, editors. 3rd edition. Little, Brown and Co. Boston, MA. 329–352.
25. Knudsen GM, Hasselbalch S, Toft PB, Christensen E. Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. *J Inherit Metab Dis*. 1995; **18**:653–664.
26. Shulkin BL, Betz AL, Koeppe RA, Agranoff BW. Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine. *J Neurochem*. 1995; **64**:1252–1257.
27. Möller HE, et al. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. *Brain Res*. 1997; **778**:329–337.
28. Gruetter R, Novotny EJ, Boulware SD, Rothman DL, Shulman RG. ¹H NMR studies of glucose transport in the human brain. *J Cereb Blood Flow Metab*. 1996; **16**:427–438.
29. Hughes JV, Johnson TC. Abnormal amino acid metabolism and brain protein synthesis during neural development. *Neurochem Res*. 1978; **3**:381–399.
30. Binek-Singer PA, Johnson TC. The effects of chronic Hyperphenylalaninemia on mouse brain protein synthesis can be prevented by other amino acids. *Biochem J*. 1982; **206**:407–414.
31. Dingledine, R., and McBain, C.J. 1993. Excitatory amino acid neurotransmitters. In *Basic neurochemistry*. G.J. Siegel, B.W. Agranoff, R.W. Albers, and R. Katzman, editors. 5th edition. Raven Press. New York, NY. 367–387.
32. DeLorey, T.M., and Olsen, R.W. 1993. GABA and glycine. In *Basic neurochemistry*. G.J. Siegel, B.W. Agranoff, R.W. Albers, and R. Katzman, editors. 5th edition. Raven Press. New York, NY. 389–399.
33. Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ER. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. *Child Dev*. 1990; **61**:1697–1713.
34. Bickel H, Gerrard J, Hickmans EM. The influence of phenylalanine intake on the chemistry and behaviour of a phenylketonuric child. *Acta Paediatr Scand*. 1954; **43**:64–77.
35. Medical Research Council Working Party on Phenylketonuria. Recommendations on the dietary management of phenylketonuria. *Arch Dis Child*. 1993; **68**:426–427.
36. Weglage J, Fünders B, Wilken B, van Teeffelen-Heithoff A, Ullrich K. Treatment of phenylketonuria: wish and reality. *Monatsschr Kinderheilkd*. 1993; **141**:670–674.
37. Pietz J, et al. Psychiatric disorders in adult patients with early-treated phenylketonuria. *Paediatrics*. 1997; **99**:34–350.
38. Pietz J, et al. Effect of high-dose tyrosine supplementation in adults with phenylketonuria. *J Pædiatr*. 1995; **127**:1–8.
39. Berry HK, Bofinger MK, Hunt MM, Phillips PJ, Guilfoile MB. Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine. *Pædiatr Res*. 1982; **16**:751–755.
40. Vorhees CV, Berry HK. Branched chain amino acids improve complex maze learning in rat offspring prenatally exposed to Hyperphenylalaninemia: implications for maternal phenylketonuria. *Paediatr Res*. 1989; **25**:568–572.
41. Hommes FA. The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in Hyperphenylalaninemia. *J Inherit Metab Dis*. 1989; **12**:41–46.
42. Pratt OE. Transport inhibition in the pathology of phenylketonuria and other inherited metabolic diseases. *J Inherit Metab Dis*. 1982; **5**(Suppl. 2):75–81.
43. Dotremont H, Francois B, Diels M, Gillis P. Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. *J Inherit Metab Dis*. 1995; **18**:127–130.
44. Huether G, Kaus R, Neuhoff V. Amino acid depletion in the blood and brain tissue of hyperphenylalaninemic rats is abolished by the administration of additional lysine: a contribution to the understanding of the metabolic defects in phenylketonuria. *Biochem Med*. 1985; **33**:334–341.
45. Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N. Early-treated phenylketonuria: adult neuropsychologic outcome. *J Paediatr*. 1994; **124**:388–392.
46. Mönch E, Herrmann M-E, Brösicke H, Schöffner A, Keller M. Utilisation of amino acid mixtures in adolescents with phenylketonuria. *Eur J Paediatr*. 1996; **155**(Suppl. 1):S115–S120.